Canada Markets open in 4 hrs 28 mins

Small Pharma Inc. (DMT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.6900+0.0900 (+15.00%)
At close: 3:59PM EDT
Full screen
Previous Close0.6000
Open0.6000
Bid0.6500 x N/A
Ask0.6900 x N/A
Day's Range0.5500 - 0.7000
52 Week Range0.2500 - 1.1000
Volume552,181
Avg. Volume95,589
Market Cap218.592M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

    Lead candidate SPL026 granted MHRA Innovation Passport DesignationLONDON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”), Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from

  • GlobeNewswire

    Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

    Enables Access for U.S. Investors to Support Small Pharma’s Vision to Broaden the Mental Health Treatment LandscapeLONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its successful upgrade from the OTC Pink to the OTCQB® Venture Market (the “OTCQB”), a United States trading platform that is operated by the OTC Markets Group Inc. in

  • GlobeNewswire

    First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

    Phase IIa to explore the effectiveness of DMT in combination with psychotherapy for the potential treatment of Major Depressive Disorder Program remains on track for topline results in H1 2022 LONDON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that the first patient has been dosed in the Company’s Phase IIa clinical trial for its lead N,N-dimethyltrypta